Gene · 10
Papers3,552
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 3,552
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management. | Front Nutr | 2022 | 35757255 | PubTator, text mining | PubMed |
| Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. | Acta Pharm Sin B | 2022 | 35755285 | PubTator, text mining | PubMed |
| NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. | Mol Genet Genomic Med | 2022 | 35751408 | PubTator, text mining | PubMed |
| Derivation of splice junction-specific antibodies using a unique hapten targeting strategy and directed evolution. | N Biotechnol | 2022 | 35750288 | PubTator, text mining | PubMed |
| Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects. | Biomedicines | 2022 | 35740242 | PubTator, text mining | PubMed |
| Are Virulence and Antibiotic Resistance Genes Linked? A Comprehensive Analysis of Bacterial Chromosomes and Plasmids. | Antibiotics (Basel) | 2022 | 35740113 | PubTator, text mining | PubMed |
| Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity. | Xenobiotica | 2022 | 35723590 | PubTator, text mining | PubMed |
| Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy. | Glob Med Genet | 2022 | 35707778 | PubTator, text mining | PubMed |
| Network pharmacology and molecular docking approach to elucidate the mechanisms of Liuwei Dihuang pill in diabetic osteoporosis. | J Orthop Surg Res | 2022 | 35701780 | PubTator, text mining | PubMed |
| Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer. | Eur J Med Res | 2022 | 35698180 | PubTator, text mining | PubMed |
| Low Prevalence of ETV6::RUNX1 Fusion Gene in a Hispanic Population. | Front Pediatr | 2022 | 35685921 | PubTator, text mining | PubMed |
| Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. | J Antimicrob Chemother | 2022 | 35678468 | PubTator, text mining | PubMed |
| Hair Dye Ingredients and Potential Health Risks from Exposure to Hair Dyeing. | Chem Res Toxicol | 2022 | 35666914 | PubTator, text mining | PubMed |
| Hexavalent chromium increases the metabolism and genotoxicity of aromatic amine carcinogens 4-aminobiphenyl and β-naphthylamine in immortalized human lung epithelial cells. | Toxicol Appl Pharmacol | 2022 | 35662664 | PubTator, text mining | PubMed |
| Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. | Contemp Clin Trials | 2022 | 35660539 | PubTator, text mining | PubMed |
| Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study. | Lancet Microbe | 2022 | 35659902 | PubTator, text mining | PubMed |
| Clinical standards for the dosing and management of TB drugs. | Int J Tuberc Lung Dis | 2022 | 35650702 | PubTator, text mining | PubMed |
| Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. | Arch Toxicol | 2022 | 35648190 | PubTator, text mining | PubMed |
| Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management. | Pharmaceutics | 2022 | 35631576 | PubTator, text mining | PubMed |
| Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers. | J Pers Med | 2022 | 35629211 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10/papers?page=23